Get started
Work

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

Year: 2019
Type: article
DOI: 10.1016/j.ygyno.2019.04.017
Authors: U.A. Matulonis, B.J. Monk, A.A. Secord, M.A. Geller, D.S. Miller, N.G. Cloven, G.F. Fleming, A.E. Wahner Hendrickson, M. Azodi, P.A. DiSilvestro, A.M. Oza, M. Cristea, J.S. Berek, J.K. Chan, Y. Li, K. Luptakova, S.J. Hazard, K.N. Moore
Institutions: Harvard University, University of Arizona College of Medicine- Phoenix, Duke University Health System, Duke Cancer Institute, University of Minnesota, The University of Texas Southwestern Medical Center, Texas Oncology, University of Chicago, Mayo Clinic, Yale University, Smilow Cancer Hospital, Brown University, University Health Network, Princess Margaret Cancer Centre, City Of Hope National Medical Center, Stanford Cancer Institute, Sutter Health, Tesaro (United States), OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2954667302
FWCI: 0.363
Cites:
Cited by: 7
Related to: 10